Whitehawk CEO to Join Jones Trading Post-AACR Fireside Chat
Event summary
- Whitehawk Therapeutics CEO Dave Lennon, PhD, to participate in a virtual fireside chat on April 23, 2026, at 3 PM ET.
- Event part of the Jones Trading Post-AACR Fireside Chat Series.
- Webcast available live and for replay on Whitehawk's IR website for 30 days.
- Whitehawk's ADC portfolio licensed from WuXi Biologics under an exclusive agreement.
The big picture
Whitehawk's participation in the Jones Trading Post-AACR Fireside Chat Series underscores the growing importance of ADC technologies in oncology. The event provides a platform for Whitehawk to highlight its differentiated approach to overcoming limitations of first-generation ADCs, potentially attracting investor and partner interest. The company's exclusive agreement with WuXi Biologics positions it within a competitive landscape of biotech firms racing to deliver next-generation cancer treatments.
What we're watching
- Strategic Messaging
- How Whitehawk positions its ADC portfolio against competitors in the oncology space.
- Investor Sentiment
- Whether the fireside chat shifts market perception of Whitehawk's clinical-stage assets.
- Partnership Dynamics
- The pace at which Whitehawk advances its licensed assets from WuXi Biologics.
Related topics